ABCG2 and cancer: Since the discovery of the P-glycoprotein (Pgp or MDR1) over 35 years ago, some studies have linked ABC transporter expression to poor outcome in several cancer types, leading to the development of Pgp inhibitors tested in clinical trials to overcome MDR [8].